What You Should Know:
- Seven Bridges, a bioinformatics ecosystem provider, announced it is collaborating with the University of São Paulo (USP) and Google Cloud, as well as the Associação Genomas Brasil (Brazil Genome Association), to assist the DNA do Brasil (DNABr) project in building a reference genome that represents the genetic diversity of the Brazilian population.
- The joint effort will advance unbiased precision medicine for underrepresented populations in Brazil through the
Read More
genomics
Golden Valley Memorial Goes Live on MEDITECH Expanse Genomics
What You Should Know:
- MEDITECH announces that Golden Valley Memorial Healthcare (GVMH) is their first client to go live on Expanse Genomics, opening the organization’s possibilities for delivering precision medicine by allowing them to analyze and parse genetic results into discrete, actionable data, displayed directly in patient charts.
- Providers can order genetic testing directly in Expanse, and the results will be received and stored in a codified format along with full PDF reports
Read More
C2i Genomics Brings Distributed Cancer Monitoring to Cancer Centers Across Europe
What You Should Know:
- C2i Genomics, a cancer intelligence company launches its C2inform minimal residual disease (MRD) test across Europe, after obtaining CE-IVD marking in the EU, UK and Switzerland. The company also announced the completion of several clinical trials across the globe, including leading cancer centers in Europe, U.S. and Singapore.
- The new clinical data will be presented at the 2022 American Association for Cancer Research (AACR) annual meeting in New Orleans,
Read More
Potential of Implementing Polygenic Risk Scores in Healthcare Systems
The promise of personalized medicine is a world in which interventions, screening, and therapeutics are targeted to those most likely to get the disease. Polygenic risk scores will help society reach this ambition by accurately assessing the contribution that one’s DNA makes to disease risk.
When Thomas Jefferson wrote in the Declaration of Independence that ‘all men are created equal,’ he captured the essential concept of equality on which the US Constitution is based. Although no one would
Read More
Invitae Launches Genomics-Forward Digital Health Platform
What You Should Know:
- Invitae launches a seamless digital platform to enhance patient and provider experiences and further bring genetics to mainstream medicine.
- Offering seamless integrations with EHR solutions, Invitae Digital Health will provide healthcare systems with a customizable suite of tools in a single, intuitive platform.
Invitae, a San Francisco, CA, based medical genetics company, announced the launch of Invitae Digital Health—a connected
Read More
Why Mainstream Precision Medicine Hinges on Healthcare HPC Storage
The healthcare industry is experiencing a data deluge, and it shows no sign of slowing down.
In 2020, estimates reported that healthcare data comprised a staggering 30% of the world’s total data volume; projections for 2025 bump that number up to 36%, a growth rate outpacing every other industry.
This is promising news for precision medicine, the data-driven healthcare initiative that promotes the right treatment for the right patient at the right time.
Precision (or personalized)
Read More
Foresite Capital Raises $173M Fund for Foresite Labs Incubated Companies
What You Should Know:
- Foresite Capital is announcing their latest, oversubscribed $173M fund, which will be used to support Foresite Labs’ incubated life science companies.
- Foresite Labs was created in October 2019 to found, build, and scale life sciences companies at the intersection of healthcare and data science. One of Foresite Capital’s core beliefs is that by combining machine learning, big data, and genomics, life sciences companies can accelerate commercialization from decades
Read More
Black Female Co-founders CancerIQ Raises $14M to Improve Cancer Early Detection and Prevention
What You Should Know:
- CancerIQ, a Chicago-based platform powering early cancer detection and prevention across broad patient populations, announced today it closed a $14M Series B financing round.
- The Series B round was co-led by Merck Global Health Innovation Fund (Merck GHI) and Amgen Ventures with participation from McKesson Ventures, OSF Ventures (the investment arm of OSF HealthCare, a current CancerIQ customer), and HealthX Ventures.
Inequality in
Read More
Sema4, BioSymetrics Partner to Advance Data-Driven Drug Discovery
What You Should Know:
- Today, Sema4, a leader in AI-driven clinical data intelligence, announced that they have partnered with BioSymetrics, to accelerate the advancement of drug discovery and new treatments for patients and pharmaceutical companies.
- Together the two will leverage Sema4’s Centrellis®, one of the largest and fastest-growing integrated health information platforms that includes approximately 12 million de-identified clinical records, and Elion, BioSymetrics’
Read More
C2i Genomics, Twist Bioscience Partner to Develop Whole-Genome Cancer Reference Materials
What You Should Know:
- Today, Twist Bioscience and cancer genomics startup C2i Genomics announced a partnership to develop whole-genome cancer reference materials.
- This resource will provide diagnostic labs around the globe with the ability to better validate and monitor the quality of their whole-genome cancer screening and minimal residual disease (MRD) products for more accurate cancer detection.
C2i to integrate Twist’s library preparation kits into minimal residual
Read More
